Abstract
Hemopoietic stem cells (HSCs) are commonly used for curing malignant and nonmalignant hematopoiesis disorders. In recent years, HSC potential giving rise to multilineage progeny has been reported. This issue, together with their availability and number, has made them ideal candidates for β-cell replacement in diabetic patients. HSC capacity to differentiate to insulin-producing cells has been at the center of debate for the past 5 years and it now seems that their role could more likely be that of helper cells able to facilitate survival or stimulate proliferation of endogenous β cells. In addition, clinical studies are ongoing about the possible use of HSCs to stop autoimmune destruction at the onset of diabetes or to induce tolerance through microchimerism in pancreatic islet transplantation.
| Original language | English |
|---|---|
| Pages (from-to) | 119-124 |
| Number of pages | 6 |
| Journal | Current Diabetes Reports |
| Volume | 9 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2009 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Internal Medicine
Cite this
The contribution of hematopoietic stem cells to beta-cell replacement. / Sordi, Valeria; Piemonti, Lorenzo.
In: Current Diabetes Reports, Vol. 9, No. 2, 2009, p. 119-124.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The contribution of hematopoietic stem cells to beta-cell replacement
AU - Sordi, Valeria
AU - Piemonti, Lorenzo
PY - 2009
Y1 - 2009
N2 - Hemopoietic stem cells (HSCs) are commonly used for curing malignant and nonmalignant hematopoiesis disorders. In recent years, HSC potential giving rise to multilineage progeny has been reported. This issue, together with their availability and number, has made them ideal candidates for β-cell replacement in diabetic patients. HSC capacity to differentiate to insulin-producing cells has been at the center of debate for the past 5 years and it now seems that their role could more likely be that of helper cells able to facilitate survival or stimulate proliferation of endogenous β cells. In addition, clinical studies are ongoing about the possible use of HSCs to stop autoimmune destruction at the onset of diabetes or to induce tolerance through microchimerism in pancreatic islet transplantation.
AB - Hemopoietic stem cells (HSCs) are commonly used for curing malignant and nonmalignant hematopoiesis disorders. In recent years, HSC potential giving rise to multilineage progeny has been reported. This issue, together with their availability and number, has made them ideal candidates for β-cell replacement in diabetic patients. HSC capacity to differentiate to insulin-producing cells has been at the center of debate for the past 5 years and it now seems that their role could more likely be that of helper cells able to facilitate survival or stimulate proliferation of endogenous β cells. In addition, clinical studies are ongoing about the possible use of HSCs to stop autoimmune destruction at the onset of diabetes or to induce tolerance through microchimerism in pancreatic islet transplantation.
UR - http://www.scopus.com/inward/record.url?scp=63349101763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63349101763&partnerID=8YFLogxK
U2 - 10.1007/s11892-009-0021-x
DO - 10.1007/s11892-009-0021-x
M3 - Article
C2 - 19323956
AN - SCOPUS:63349101763
VL - 9
SP - 119
EP - 124
JO - Current Diabetes Reports
JF - Current Diabetes Reports
SN - 1534-4827
IS - 2
ER -